Skip to content

Assessment the therapeutic effect of pantoprazole in patients with gastrointestinal bleeding

Comparison the therapeutic effects of high-dose and low-dose pantoprazole after endoscopy in patients with peptic ulcer bleeding

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201202289160N1
Enrollment
166
Registered
2012-04-15
Start date
2011-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper gastro intestinal bleeding. Diseases of oesophagus, stomach and duodenum

Interventions

Intervention 1: Pantoprazole 80 mg bolus infusion followed by 8 mg/h intravenously as maintenance dose for 72 h after endoscopic treatment. Intervention 2: Pantoprazole 80 mg bolus infusion followed b
Treatment - Drugs
Pantoprazole 80 mg bolus infusion followed by 8 mg/h intravenously as maintenance dose for 72 h after endoscopic treatment
Pantoprazole 80 mg bolus infusion followed by 4 mg/h intravenously as maintenance dose for 72 h after endoscopic treatment

Sponsors

Research Deputy of Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients who admit and present signs and symptoms of upper gastrointestinal bleeding such as: 1-Vomits of blood or black material (Hematemesis), 2-Black and tarry stool (Melena), 3-The passage of bright red or blood from the rectum (Hematochesia), 4-Vertigo; light headness and hypotension. Exclusion criteria are: 1-Malignant ulcer; 2-Multiple ulcers; 3-Cirrhotic patient with coagulopathy or hemorrhagic varices; 4-Chronic Renal Failure (CRF); 5-Patients who admitted with gastrointestinal bleeding in last month; 6-Patients receive NSAID and Corticosteroid for underlying disease; 7-Patients under 16 years or upper 70 years;8-Patients who are treated with PPI (proton pomp inhibitor) in last week.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Mean units of blood transfusde. Timepoint: In period of admission. Method of measurement: Mean units of blood transfusde in period of admission.;Duration of admission more than 5 days. Timepoint: In period of admission. Method of measurement: This time evaluate from admission to discharge.;Need for surgery. Timepoint: In period of admission. Method of measurement: According to vital signs and hemodinamicaly status.;Rebleeding. Timepoint: In period of admission. Method of measurement: According to vital signs and hemodinamicaly status.

Secondary

MeasureTime frame
Readmission due to upper gastrointestinal bleeding. Timepoint: First month after admission. Method of measurement: With take of history and hemodinamicaly status.;The mortality rate. Timepoint: First month of admission. Method of measurement: With take of history and hemodinamicaly status.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNoorodin Jamshydian

Ahvaz Jundishapur University of Medical Sciences

jamshydian.n@ajums.ac.ir , noorejam1@yahoo.com+98 33 1223 3920

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026